US Patent Issued to Dexcel Pharma Technologies on Oct. 28 for "Nucleic acids for inhibiting expression of transferrin receptor 2" (Israeli Inventors)

ALEXANDRIA, Va., Oct. 28 -- United States Patent no. 12,454,693, issued on Oct. 28, was assigned to Dexcel Pharma Technologies Ltd. (Jerusalem).

"Nucleic acids for inhibiting expression of transferrin receptor 2" was invented by Nadav Marbach-Bar (Jerusalem), Elena Feinstein (Jerusalem) and Noa Madar-Balakirski (Jerusalem).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are nucleic acids and compositions thereof for inhibiting expression of transferrin receptor 2 (TFR2). Also described are methods for treatment of TFR2-associated diseases, such as anemia, with the disclosed nucleic acids."

The patent was filed on Sept. 27, 2024, under Application No. 18/898,720.

*For further information, incl...